Reducing Side Effects of Breast Cancer Treatments with Oxytocin

Adult, Current Research, Dr. Appiah, Drug, Minority/Underrepresented, Oncology, University of Colorado, Women's Health

Principal Investigator: Dr. Leslie Appiah

Disease: Genitourinary Syndrome of Menopause in Breast Cancer Patients

Research Description: Genitourinary Syndrome of Menopause (GSM) is a condition that can cause a variety of symptoms, including urinary issues and pain, and can dramatically decrease quality of life. Up to 60% of women treated for hormone receptor-positive (HRP) breast cancer in the US experience GSM as a direct result of their cancer treatment. While estrogen is the standard of care for GSM, is contraindicated for HRP breast cancer patients due to a risk of cancer recurrence. Studies have shown that oxytocin gel may reduce the harmful side effects caused by GSM, but the potential benefits to HRP breast cancer patients have yet to be studied. This randomized, double-blind, pilot trial is studying the effectiveness of oxytocin gel to treat GSM in HRP breast cancer patients. The results of this study could improve the quality of life for the million survivors of HRP breast cancer in the US experiencing GSM.

Funding Partners: Cures Within Reach and multiple others

CWR Funding Role: Primary funder